NPPA Permits Torrent to Shift Drug Production from Akums to Sikkim

•  Torrent gets NPPA nod to shift drug manufacturing.
• Own plant in Sikkim approved for formulation production.
• Retail price remains per 2019 approved rate.

At the retail price previously authorized by the National Pharmaceutical Pricing Authority ( NPPA), Torrent Pharmaceuticals has been permitted to move the manufacturing of its combination medication for nutritional deficiencies from a contract manufacturer to its own location.The action complies with the Authority's guidelines from nearly two years ago, which permit marketing firms to continue promoting the formulation that has already been launched with a new manufacturer as long as " shifting of manufacturing to its own plant by the existing marketing entity

Following a request from the company regarding its formulation of film-coated tablets containing calcium carbonate IP 1250 mg equivalent to elemental calcium 500mg, vitamin D3 IP 2000IU, mecobalamin  IP ( methylcobalamin) 1500 mcg, I-methylfolate calcium 1mg, and pyridoxal -5-phosphate 20 mg, the decision was made in an Authority meeting held at the end of May 2025.

Also Read:Supriya Lifescience Expands Production to Strengthen Market Position

In December 2024, the business asked the NPPA to allow it to market the formulation at the rates it had announced in November 2019 while moving the formulation's production from Akums Drugs and Pharmaceuticals Ltd. to its own facility in Sikkim. The Authority deliberated upon the matter in detail and noted that in the instant case since Torrent Pharmaceuticals Ltd has applied for manufacturing the captioned formulation at its own site, the company may be permitted to market the said formulation at approved retail price, not exceeding the present applicable retail price," said the Authority, Following this, the decision was notified by the NPPA in the official Gazette.